Johnson & Johnson Announced Results From Phase 3 GRAVITI Study Of Tremfya (Guselkumab), Demonstrating Significant Clinical Remission And Endoscopic Response At 48 Weeks In Adults With Moderately To Severely Active Crohn's Disease
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced positive results from the Phase 3 GRAVITI study of Tremfya (Guselkumab) for treating Crohn's Disease, showing significant clinical remission and endoscopic response at 48 weeks.
October 28, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's Tremfya demonstrated significant clinical remission and endoscopic response in a Phase 3 study for Crohn's Disease, potentially boosting the company's stock.
The positive results from the Phase 3 GRAVITI study of Tremfya indicate a strong potential for the drug in treating Crohn's Disease, which could lead to increased sales and revenue for Johnson & Johnson. This is likely to have a positive impact on JNJ's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100